Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: A randomized, placebo-controlled and dose-finding study.

Next Previous
Trial Profile

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: A randomized, placebo-controlled and dose-finding study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lubiprostone (Primary)
  • Indications Constipation; Irritable bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sucampo Pharmaceuticals

Most Recent Events

  • 01 May 2010 Results presented at 2010 Digestive Disease Week.
  • 02 Oct 2008 New trial record.
  • 19 Sep 2008 Full results will be reported at an upcoming scientific meeting, according to a Sucampo Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top